Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Moodys
Fish and Richardson
Boehringer Ingelheim
Harvard Business School
Cerilliant
Baxter
Chinese Patent Office
Accenture

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,258,795

« Back to Dashboard

Summary for Patent: 6,258,795
Title: Acylated uridine and cytidine and uses thereof
Abstract:The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.
Inventor(s): von Borstel; Reid Warren (Darnestown, MD), Bamat; Michael Kevin (Darnestown, MD)
Assignee: Pro-Neuron, Inc. (Gaithersburg, MD)
Application Number:08/466,145
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 6,258,795

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Wellstat Therap VISTOGARD uridine triacetate GRANULE;ORAL 208159-001 Dec 11, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Wellstat Therap XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,258,795

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,583,117 Acylated uridine and cytidine for elevating tissue uridine and cytidine ➤ Sign Up
5,691,320 Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis ➤ Sign Up
6,329,350 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis ➤ Sign Up
5,736,531 Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,258,795

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2158269 ➤ Sign Up
Russian Federation 2115410 ➤ Sign Up
Portugal 1491201 ➤ Sign Up
Portugal 679160 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
McKinsey
Deloitte
Baxter
Boehringer Ingelheim
Cipla
Harvard Business School
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.